《生命科学》 2019, 31(8): 777-786
摘 要：摘 要：组蛋白去乙酰化酶6 (histone deacetylase 6， HDAC6) 属于IIb 类组蛋白去乙酰化酶家族，是一种依赖锌的，主要靶向非组蛋白的去乙酰化酶。越来越多的研究表明，HDAC6 的表达和活性在多种疾病的发生发展过程中是异常的，因此，HDAC6 被认为是潜在治疗的靶点。临床前数据表明，许多特异性靶向HDAC6 的小分子抑制剂在多种疾病的治疗中发挥作用。该文讨论了HDAC6 结构和功能的最新研究，并结合其小分子抑制剂在恶性肿瘤、神经退行性疾病、肾纤维化和自身免疫及炎症等方面的研究进展进行综述。
Abstract: Abstract: Histone deacetylase (HDAC) 6 is a zinc-dependent deacetylase which belongs to the class IIb HDAC family and mainly targets non-histone proteins. More and more evidence suggests that HDAC6 expression and activity are dysregulated in a wide range of disease states. Hence， HDAC6 has been designated as a potential therapeutic target， and preclinical data suggest that a number of small molecule specific HDAC6 inhibitors may play a role in the treatment of various diseases. This review discusses the latest research of structural features and functions of HDAC6， and focuses on the research progress of small molecule inhibitors in malignant tumors， neurodegenerative diseases， renal fibrosis， autoimmunity and inflammation.
